Galapagos and Genentech extend drug discovery deal

Published: 18-Aug-2011
Research & Development Finance

Agreement has now been extended three times since 2005


Galapagos’ service division Argenta has signed a £21.5m (US$35.5m; €23.4m) extension to its contract drug discovery agreement with Genentech.

Medicinal chemistry, in vitro biology and screening will be performed to discover new chemical entities against undisclosed drug targets chosen by Genentech.

This is the third extension since the firms started working together in December 2005.

The extended agreement also allows Genentech to continue placing projects directly with Galapagos' other service division, BioFocus, which will provide Genentech with integrated medicinal chemistry, in vitro biology and ADME services.

BioFocus has been working with Genentech since an amendment to the Argenta agreement was signed in September 2010.

  • Companies:
  • Galapagos NV
  • Genentech
See more

You may also like

Drug Delivery

Galapagos and NovAliX enter integrated drug discovery collaboration

Read more
The agreement follows Galapagos’ renewed focus on its key therapeutic areas of oncology and immunology

Trending Articles

  1. Lonza Capsules & Health Ingredients expands capsule manufacturing capacity in India and China New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari (IN) and Suzhou (CN), highlighting the long-term strategic commitment to the business and the APAC region
  2. Novo Holdings completes acquisition of Catalent Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark
  3. ACG expands global footprint with new capsule manufacturing facility in Thailand New capsule manufacturing facility in Rayong, Thailand, is strategically positioned to serve key Asian markets
  4. Newcells Biotech raises additional funding from investors Newcells Biotech, a leading drug discovery partner specialising in the development of in vitro models and bespoke assay services to improve the prediction of in vivo human outcomes, has raised a further £1.2m from existing investors Mercia Ventures, Northstar Ventures and North East Finance
  5. Thermo Fisher Scientific reveals MagMax Sequential DNA/RNA Kit to advance blood cancer research The kit combines DNA and RNA isolation chemistries into a single kit, simplifying sample extraction for a broad range of downstream molecular applications

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Drug Delivery

Galapagos and NovAliX enter integrated drug discovery collaboration

The agreement follows Galapagos’ renewed focus on its key therapeutic areas of oncology and immunology
Research & Development

Scenic Biotech enters into genetic modifier collaboration with Genentech

Multi-year strategic collaboration in target discovery and therapeutic development based on Scenic Biotech’s disease modifying approach
Research & Development

Galapagos expands fibrosis portfolio

Fibrosis small molecule programme has been announced as the focus of a partnership between Galapagos and Evotec
Research & Development

Pharnext announces R&D agreement with Galapagos

The main goal of this agreement is to generate an additional pipeline of novel synergistic drug combinations in a broad set of indications
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Optimising scale-up with flow process technologies

Speed of synthesis is of the essence when medicinal chemists invent new molecules, reports Sarah Houlton
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

ADCs: a more effective, less harmful, targeted approach

Antibody-drug conjugates could hold the key to delivering highly potent anticancer drugs more accurately to the tumour site with less damage to healthy cells
Regulatory

Rheumatoid arthritis – sarilumab

Not all patients respond well to or tolerate TNF-alpha inhibitors, and an alternative strategy might be to treat with a drug against the interleukin-6 receptor alpha
Subscribe now